Bristol-Myers Squibb Company (BMY) Q1 2015 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 0.95%

Bristol Myers Squibb's earnings report showed a strong EPS beat, indicating better-than-expected profitability. However, the stock fell by 0.95%, possibly due to the lack of revenue data and forward guidance. Investors may be cautious as the company navigates its pipeline and market conditions.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.71	N/A	+40.87%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a positive outlook regarding their product pipeline. However, they did not provide specific guidance for future quarters.

Management highlighted strong performance in key therapeutic areas.

They expressed confidence in ongoing clinical trials and pipeline development.

Bristol Myers Squibb Beats on EPS, Stock Down 0.95%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 0.95%

Key numbers

Management commentary